SCHEMBL370840

SCHEMBL370840

CCCCCc1ccn(CCCCC)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.44
HDAC1 Q13547 2/20 0.39
CYP19A1 P11511 6/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
NPC1 O15118 6/20 0.38
RAB9A P51151 6/20 0.38
HTT P42858 5/20 0.38
LMNA P02545 3/20 0.38
APOBEC3A P31941 2/20 0.38
APOBEC3G Q9HC16 2/20 0.38
ALDH1A1 P00352 1/20 0.38
PABPC1 P11940 1/20 0.38
HRH4 Q9H3N8 2/20 0.38
HRH3 Q9Y5N1 2/20 0.38
GALR3 O60755 2/20 0.37
POLB P06746 2/20 0.37
ATM Q13315 2/20 0.37
MAPK1 P28482 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27711036 0.93 KCNH2 (0.44) KCNH2HDAC1CYP19A1CNR1CNR2
SCHEMBL7016894 0.91 KDM5A (0.40) KCNH2HDAC1CYP19A1ALDH1A1POLB
SCHEMBL27710988 0.87 KCNH2 (0.46) KCNH2HDAC1CYP19A1CNR1CNR2
SCHEMBL293555 0.86 KCNH2 (0.36) KCNH2HDAC1CYP19A1CNR1CNR2
SCHEMBL8664135 0.85 KCNH2 (0.48) KCNH2HDAC1CYP19A1CNR1CNR2
SCHEMBL294176 0.84 KDM5A (0.35) KCNH2HDAC1CYP19A1CNR1CNR2
SCHEMBL28063315 0.83 MIF (0.36) KCNH2HDAC1CYP19A1HRH4HRH3
SCHEMBL294516 0.82 KDM5A (0.33) KCNH2HDAC1CYP19A1ALDH1A1POLB
Quinoline SCHEMBL27743469 0.82 ALDH1A1 (0.42) KCNH2HDAC1CNR1CNR2HTT
SCHEMBL2629293 0.81 KCNH2 (0.47) KCNH2CYP19A1CNR1CNR2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113347969-A Composition for eliminating senescent cells 维也纳自然资源与生命科学大学 2021-09-03 CN claimed
CN-111065391-A Compositions containing conjugates of cannabinoid analogs and methods of use 维利法姆企业有限责任公司 2020-04-24 CN claimed
EP-1680116-A1 COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS Solvay Pharmaceuticals GmbH (DE) 2006-07-19 EP claimed
EP-1200094-B1 OPHTHALMIC COMPOSITIONS CONTAINING ANTIBIOTICS AND NSAIDS ALLERGAN INC (US) 2006-06-21 EP claimed
EP-1663215-A1 NOVEL MEDICAL USE OF SELECTIVE CB1- RECEPTOR ANTAGONISTS Solvay Pharmaceuticals GmbH (DE) 2006-06-07 EP claimed
US-20050101585-A1 Use of selective CB1-antagonists in medical treatments SOLVAY PHARMACEUTICALS GMBH (DE) 2005-05-12 US claimed
WO-2005039579-A1 COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS SOLVAY PHARMACEUTICALS GMBH (DE) 2005-05-06 WO claimed
WO-2005020992-A1 NOVEL MEDICAL USE OF SELECTIVE CB1-RECEPTOR ANTAGONISTS SOLVAY PHARMACEUTICALS GMBH (DE) 2005-03-10 WO claimed
WO-2024125320-A1 USE OF DIPYRIDAMOLE AND PREPARATION THEREOF IN PREVENTING AND TREATING ATOPIC DERMATITIS 智泽童康(广州)生物科技有限公司 2024-06-20 WO disclosed
WO-2024110503-A1 METHODS FOR TREATING EYETEAR FILM DEFICIENCY BAUSCH + LOMB IRELAND LIMITED (IE) 2024-05-30 WO disclosed
WO-2024110505-A1 METHODS FOR TREATING EYETEAR FILM DEFICIENCY BAUSCH + LOMB IRELAND LIMITED (IE) 2024-05-30 WO disclosed
US-20240165147-A1 Methods for Treating Eyetear Film Deficiency JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2024-05-23 US disclosed
US-20240165019-A1 Methods for Treating Eyetear Film Deficiency JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2024-05-23 US disclosed
US-20240102034-A1 CANNABIS PLANT WITH INCREASED CANNABIGEROLIC ACID CANOPY GROWTH CORPORATION (CA) 2024-03-28 US disclosed
WO-1995015315-A1 1,5-DIPHENYL PYRAZOLE COMPOUNDS FOR TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1995-06-08 WO disclosed
CN-1026695-C Synthesis of N-tertiary alkyl-1, 2-diacylhydrazines ROHM & HAAS (US) 1994-11-23 CN disclosed
EP-0248594-B1 Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same ORTHO PHARMA CORP (US) 1993-11-24 EP disclosed
US-5164381-A Cardiovascular, antiinflammatory ORTHO PHARMACEUTICAL CORPORATION (US) 1992-11-17 US disclosed
US-4826868-A 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use ORTHO PHARMACEUTICAL CORPORATION (US) 1989-05-02 US disclosed
EP-0248594-A2 Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same ORTHO PHARMACEUTICAL CORPORATION (US) 1987-12-09 EP disclosed